Our Voice at the 48th Congress of the Polish Psychiatric Association

Our activities are not limited solely to research work. An equally important element of the development of CBK PI-HOUSE is being present where key discussions about the future of psychiatry take place. For this reason, at the beginning of September, we had the pleasure of participating – as a psychiatric and psychological team – in the 48th Congress of the Polish Psychiatric Association, where we shared our experience and knowledge in the field of clinical research on psychedelic substances, with particular emphasis on ethical aspects. This is the most important event in the Polish psychiatric community, held every two years and bringing together leading experts, researchers, and practitioners from across the country.

Our priority during the event was to learn about the latest research findings on psychedelic substances in the treatment of psychiatric and neurological disorders and to understand the current perspective of the scientific community on this therapeutic area. At the same time, we had the opportunity to present our vision for the development of clinical research on psychedelics, emphasizing the importance of quality and ethics in this field.

Clinical trials involving psychedelic substances represent not only great therapeutic potential but also significant methodological challenges. Conducting such studies requires exceptional attention to the quality of research processes and adherence to the highest ethical standards. At CBK PI-HOUSE, we believe that ethics and quality are the foundation of all research activities, and without their consistent implementation, meaningful scientific and clinical progress is not possible.

As a result of collaboration with the team of Dr. Justyna Holka–Pokorska and the Polish Psychedelic Society, represented by Maciej Lorenc, a joint thematic session was organized:

“Psychedelics and the commercialization of mystical experiences in medical, therapeutic, and destructive cult contexts.”

During this session, Dr. Hanna Badzio-Jagiełło, Head of the CNS (Central Nervous System) Team, presented on behalf of CBK PI-HOUSE and Penta Hospitals Polska the topic “Clinical and ethical challenges of using psychedelics in commercial clinical trials.”

We noted with satisfaction that the subject of quality and ethics in psychedelic research are gaining increasing recognition within the psychiatric community. This is evidenced, among other things, by the fact that more than 10% of the Congress time – dedicated to all key diagnostic, therapeutic, and organizational issues in Polish psychiatry – was specifically devoted to ethical considerations.

We are proud of our active participation in one of the most important psychiatric events in Poland. Our participation in the 48th Congress of the Polish Psychiatric Association confirmed that CBK PI-HOUSE plays a significant role in advancing research on the use of psychedelic substances in the treatment of central nervous system disorders.

Our commitment and determination to deepen knowledge and analyse the complexity of psychedelic research stem from a strong belief that science should primarily serve people. Therefore, our goal is not only to expand the boundaries of knowledge but, above all, to create safe, reliable, and groundbreaking clinical projects that may fundamentally transform the treatment of psychiatric and neurological disorders in the future.

At CBK PI-HOUSE and Penta Hospitals Poland, we combine science, ethics, and innovation so that psychedelic research can truly shape the future of psychiatry and improve patients’ quality of life.